case_images: PMC10725144_01
case_images: Imaging studies in Case 1 during treatment. (a) Positron emission tomography/computed tomography at presentation (April - 2019). (b) Two months of treatment with olaparib plus IVC (75 g/day, 2-3 times a week; July - 2019). (c) Progression after continuing single-agent olaparib without IVC (November - 2019). (d) Retreatment with talazoparib plus IVC. Once again, a response was achieved, although it was not as strong as the first time (February - 2020).. IVC, intravenous vitamin C.
case_images: 10.1177_17588359231213841-fig3.jpg
case_images: PMC10725144_01_10.1177_17588359231213841-fig3.jpg
case_images: fig3-17588359231213841
case_images: After 2 months, a response evaluation using CT and PET revealed a dramatic response [Figure 3(a) and (b)]. PET/CT revealed tumor progression [Figure 3(c)]. After the resumption of IVC therapy, therapeutic response was achieved again [Figure 3(d)].
case_images: PMC10725144_02
case_images: Case 2 imaging studies during treatment. Initial 
  
  F-fluorodeoxyglucose positron emission tomography/computed tomography (CT) (a and b) for staging revealed solid-cystic bulky tumors (white arrows) with an extremely high maximum standardized uptake value extending to the retroperitoneum in the right upper quadrant of the abdomen. After treatment, follow-up CT (c) revealed marked shrinkage of the tumor (yellow arrows), which was considered a partial response.. CT, computed tomography.
case_images: 10.1177_17588359231213841-fig4.jpg
case_images: PMC10725144_02_10.1177_17588359231213841-fig4.jpg
case_images: fig4-17588359231213841
case_images: Dramatic clinical and radiological responses were achieved 1 month later (Figure 4).